Finasteride
TabletHair Loss
TabletHair LossIn stock
Dutasteride tablet
A dual 5-alpha-reductase inhibitor positioned as the stronger-DHT step up from finasteride, for hair-loss programs that want an answer for finasteride non-responders, on top of the intake, provider-review, and refill infrastructure the rest of the catalog runs on.
Cadence
Once daily
Serum DHT drop
~90%+
Format
0.5 mg oral tablet, once daily
Label status
FDA-approved for BPH, off-label for hair loss
Rx required
Yes, licensed provider review
Counseling
Sexual side effects and long half-life
About the protocol
The stronger DHT blocker for finasteride non-responders
Dutasteride inhibits both type I and type II 5-alpha-reductase, while finasteride mainly inhibits type II. That dual action drives a larger reduction in serum DHT, often cited above 90% versus roughly 70% for finasteride. Dutasteride is FDA-approved as Avodart for benign prostatic hyperplasia and is used off-label for androgenetic alopecia in the U.S. A 2025 randomized comparison reported a higher rate of marked improvement for dutasteride than for once-daily finasteride, which is why programs increasingly position it as the step-up option.
- Dual 5-alpha-reductase inhibition lowers scalp and serum DHT more completely than finasteride
- Useful as a step up for patients who plateau or do not respond on finasteride
- Off-label for hair loss in the U.S., so public copy should frame it as a provider-directed option
- Long half-life and the same pregnancy-handling cautions as finasteride belong in intake and counseling
Mechanism
Dual type I and II 5-alpha-reductase inhibitor, for more complete DHT suppression.
Delivery
Once-daily 0.5 mg oral tablet taken at a consistent time, with or without food.
Persistence
A long terminal half-life means effects and washout extend well beyond a single dose.
Oversight
Provider review covers eligibility, sexual side-effect counseling, and continuation.
Program design
The step-up Rx in a maturing hair-loss program
Dutasteride is rarely the first molecule a brand launches. It earns its place once a program already runs finasteride and needs a credible answer for non-responders and patients who want a stronger option, without leaving the same operational footprint.
Stronger DHT suppression
The dual-inhibitor mechanism is the clearest reason to offer it alongside, or after, finasteride.
Recurring by design
Like finasteride, benefit is maintained only while treatment continues, which fits monthly refill economics.
Counseling matters more
Off-label status, a longer half-life, and the sexual side-effect profile all need structured disclosure at intake.
Dutasteride is not FDA-approved for hair loss in the U.S. and is not for use by women who are pregnant or may become pregnant. Encode handling and contraindication rules into intake and order routing.
Launch flow
A simple launch flow for oral dutasteride
The cleanest setup keeps the patient flow short, routes every order through a licensed provider, and uses refill check-ins to confirm tolerability and response over time.
- 1Step 1Intake and eligibilityCollect pattern and duration of loss, prior finasteride response, medications, history, and sexual-health baseline, then screen for contraindications.
- 2Step 2Provider review and counselingThe provider confirms AGA fit, explains the off-label and stronger-suppression context, counsels on side effects, and approves a starting supply if appropriate.
- 3Step 3Refill and continuation reviewUse follow-ups to assess tolerability, baseline photos, and whether to continue, pause, or combine with topical or oral minoxidil.
Because dutasteride persists in the body longer than finasteride, set expectations that both onset and washout play out over a longer window than patients may assume.
Format comparison
Interactive operator view
Compare how oral dutasteride usually behaves operationally versus oral finasteride in a hair-loss program. These are planning dimensions, not clinical outcome comparisons.
Format comparison by operator dimension
Hover to compare dutasteride versus finasteride.
DutasterideFinasteride
Strongest current edge
Male AGA fit
Dutasteride scores 94/100 on this dimension.
Clearest difference
Non-responder fit
This is where the two NAD+ formats separate the most in program design terms.
Needs the most support
U.S. label clarity
This is the weakest current score in the comparison, so it is the area most likely to need extra workflow design.
Illustrative operator-planning view based on mechanism strength, label scope, and typical patient fit. Not a statement of safety or efficacy for any individual patient.
The Turbopills stack for this program
Everything you need to run a dutasteride program
Use your own brand, your own providers, and your own price. The platform ships the intake, provider-review workflow, order routing, billing, and refill logic, so your team focuses on acquisition.
Product website & ad landing pages
Turbopills AI Studio — ad images & videos
BetaProvider review & e-Rx
Pharmacy order routing
Refills & auto-ship
Experiments & A/B tests
BetaReady to launch
Add a stronger-DHT option without adding operational work.
The platform ships the intake flow, provider-review logic, side-effect counseling scripts, billing, and refill cadence for dutasteride. Plug in your licensed providers and pharmacy partners, and your team focuses on getting the right patients in the door.
Marketing and educational content only. Clinical details on this page are summarized from publicly available sources to help operators scope a program — they are not medical advice, dosing instructions, or a recommendation for any individual patient. Real patient care requires a licensed provider and a compliant pharmacy partner; Turbopills provides the software that helps brands run the program around them.
Related
